CDSCO approves Trastuzumab Deruxtecan for first-line HER2-positive breast cancer
Approval expands indication for Trastuzumab Deruxtecan in combination with Pertuzumab for adults with unresectable or metastatic…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Trastuzumab deruxtecan
AstraZeneca’s Trastuzumab deruxtecan therapy receives CDSCO nod to manage HER2- low & ultra-low…
The medicine is now indicated as a monotherapy for the treatment of adult patients with unresectable or metastatic breast cancer
Decoding Budget 2024-25: A lacklustre budget for pharma
The Finance Minister announced the Budget for 2024-25 on July 23, during the Monsoon Session of Parliament
Enhertu shows positive results in DESTINY-Breast06 Phase III trial
Demonstrates statistically significant and clinically meaningful improvement in progression-free survival in HR-positive, HER2-low…
AstraZeneca India gets dual CDSCO approval for Trastuzumab deruxtecan
Additional indications for treatment of HER2 low breast cancer and HER2 positive gastric / gastro-oesophageal cancer